(Belga) In France, five cases of myocarditis (inflamed heart muscle) have been identified in people vaccinated with the Pfizer / BioNTech COVID-19 vaccine. A link with the vaccine has not been established at this time, it sounds to health authorities on Friday.
“The available data at this stage does not provide enough elements to draw a conclusion on the role of the vaccine, but nevertheless represents a potential signal to be monitored,” said the French medicines authority ANSM. The ball started to roll after myocarditis was diagnosed in young men in Israel after a second Pfizer shot. In France, five cases have now come to light and the data will be shared at European level. The ANSM emphasizes that these possible side effects “do not outweigh the beneficial benefits of the vaccine at the moment”. In France, a total of 16,030 cases of adverse reactions following a Pfizer / BioNTech vaccination have been analyzed in France since the start of the vaccination campaign. Usually these are non-serious complaints, such as pain at the injection site or headache. An additional case of atypical thrombosis has been reported for the AstraZeneca vaccine, reserved in France for people over 55 years of age. The profile of that patient is similar to that of the previous cases. A total of 28 reports of atypical thrombosis after vaccination have already been made in France, eight people died. (Belga)
“The available data at this stage does not provide enough elements to draw a conclusion on the role of the vaccine, but nevertheless represents a potential signal to be monitored,” said the French medicines authority ANSM. The ball started to roll after myocarditis was diagnosed in young men in Israel after a second Pfizer shot. In France, five cases have now come to light and the data will be shared at European level. The ANSM emphasizes that these possible side effects “do not outweigh the beneficial benefits of the vaccine at the moment”. In France, a total of 16,030 cases of adverse reactions following a Pfizer / BioNTech vaccination have been analyzed in France since the start of the vaccination campaign. Usually these are non-serious complaints, such as pain at the injection site or headache. An additional case of atypical thrombosis has been reported for the AstraZeneca vaccine, reserved in France for people over 55 years of age. The profile of that patient is similar to that of the previous cases. A total of 28 reports of atypical thrombosis after vaccination have already been made in France, eight people died. (Belga)
–
